INTRODUCTION
Gastric cancer, cancers, cancer death, cancer, CRS, (CMT)As
GASTRIC CANCER, CANCERS, METASTASIS, CANCER, CAVITY, PERITONEAL DISSEMINATION, METASTASES, TUMOR RECURRENCE
Gastric cancer (GC) is one of the most common cancers, and despite advances in diagnosis and treatment, it remains an important cause of cancer death worldwideAmong metastatic GC cases, peritoneal dissemination is an important site of progression and tumor recurrence after initial curative intent treatmentPC is a definitive determinant of prognosis, and the current standard treatment in these cases is systemic chemotherapy (CMT)As other therapeutic options, some studies investigating the effect of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases, have suggested an improvement in survival in strictly selected patientsAs intraperitoneal administration of anticancer drugs can induce an extremely high concentration of drugs in the peritoneal cavity, allowing direct contact with peritoneal deposits and free cancer cells in the cavity, IPC seems to be a promising treatment for GC with peritoneal metastasisTo date, taxanes appear to be the most appropriate drugs for intraperitoneal administration to treat peritoneal metastasis of GC – either alone or in combination with systemic chemotherapyThus, this study was designed to investigate the role of IPC in stage IV GC patients with peritoneal metastasis. The main objective is to evaluate the rate of complete peritoneal response after treatment with normothermic IPC associated with systemic CMT. The current trial is the first in Brazil to evaluate this treatment option for PC, and the results may contribute to a tailored approach to the treatment of patients with GC.